Tempus AI (NASDAQ:TEM) Raised to “Hold” at Wall Street Zen

Tempus AI (NASDAQ:TEM) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts also recently weighed in on the company. Wolfe Research started coverage on Tempus AI in a report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Jefferies Financial Group initiated coverage on shares of Tempus AI in a report on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research report on Monday, July 20th. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Finally, Guggenheim boosted their target price on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $68.92.

Tempus AI Stock Performance

Shares of TEM stock opened at $42.69 on Friday. The firm has a market cap of $7.67 billion, a price-to-earnings ratio of -24.82 and a beta of 3.46. Tempus AI has a 52-week low of $41.73 and a 52-week high of $104.32. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The company’s 50 day moving average is $51.65 and its 200 day moving average is $53.49.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The business had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company’s quarterly revenue was up 36.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.24) earnings per share. On average, sell-side analysts anticipate that Tempus AI will post -1.35 EPS for the current fiscal year.

Insider Activity at Tempus AI

In other news, Director Jennifer A. Doudna sold 2,673 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $147,015.00. Following the completion of the transaction, the director directly owned 25,942 shares in the company, valued at $1,426,810. This trade represents a 9.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James William Rogers sold 11,529 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $634,095.00. Following the completion of the transaction, the chief financial officer owned 114,866 shares of the company’s stock, valued at approximately $6,317,630. The trade was a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 616,043 shares of company stock worth $31,748,593 in the last quarter. 24.26% of the stock is owned by insiders.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Tempus AI by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after buying an additional 817,014 shares during the last quarter. ARK Investment Management LLC boosted its holdings in shares of Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after acquiring an additional 381,816 shares during the last quarter. GC Wealth Management RIA LLC acquired a new stake in shares of Tempus AI in the fourth quarter worth $399,267,000. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. raised its holdings in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after purchasing an additional 821,490 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.